Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Future of Exosome-Based Nanotherapeutics Effective for Pneumonia Associated Acute Lung Injury.

Created on 16 Nov 2026

Authors

Aiping Zou, Yeqing Tao, Yuwen Wang, Yafang Li

Published in

International journal of nanomedicine. Volume 21. Pages 655957. Epub Nov 11, 2026.

Abstract

Severe pneumonia can progress to acute respiratory distress syndrome (ARDS), yet effective adjunctive therapies targeting host-mediated lung injury remain limited. Exosome-based nanotherapeutics have emerged as promising cell-free candidates capable of modulating multiple pathological processes. This narrative review examines their therapeutic mechanisms, delivery strategies, engineering advances, and translational challenges in pneumonia-associated lung injury. Preclinical studies suggest that extracellular vesicle (EV) preparations, frequently described as exosomes, may attenuate inflammatory responses, preserve alveolar-capillary barrier integrity, mitigate oxidative stress and regulated cell death, and promote tissue repair. However, most evidence derives from lipopolysaccharide-induced, sepsis-associated, and other non-infectious acute lung injury (ALI) models, whereas direct evidence from pathogen-confirmed pneumonia models remains limited. Although infectious and non-infectious lung injury share important pathological mechanisms, differences in pathogen clearance and host immune responses restrict direct extrapolation. Human evidence remains limited to early clinical investigations, and therapeutic efficacy has not been established. Major translational challenges include product heterogeneity, insufficient standardization and potency assessment, uncertain functional delivery, and unresolved questions regarding dosing, safety, and patient selection. Future development requires rigorous product characterization, optimized pulmonary delivery, infection-relevant preclinical validation, and well-designed clinical trials. Overall, exosome-based nanotherapeutics offer potential as adjunctive interventions, but their clinical utility in pneumonia-associated lung injury remains to be determined.

PMID:
43036701
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement